FGFR1 Amplification in Squamous Cell Carcinoma of the Lung with Correlation of Primary and Metastatic Tumor Status.

BACKGROUND The FGFR1 gene can be amplified in squamous cell carcinoma of the lung (SqCC). The aim of this study was to compare FGFR1 status with stage and matched primaries with metastases. METHODS Cases with FGFR1 fluorescence in situ hybridization (FISH) testing performed from 2000 to 2013 were evaluated for amplification status and clinicopathologic features. RESULTS Of the 336 cases tested by FGFR1 FISH, 52 (15%) were positive for amplification. Eight (13%) of 60 N0 cases and eight (17%) of 46 N1 or N2 cases were amplified, with no statistically significant difference. Of the 24 cases with matched primary and metastatic tumors, 22 (92%) were synchronous and one (4%) had discordant amplification. CONCLUSIONS Frequency of FGFR1 amplification is similar in SqCC with and without lymph node metastases, but status in metastatic sites may be discordant from the primary in a small subset of cases, which may affect the decision to perform testing of metastatic SqCCs.

[1]  G. Bepler,et al.  Fibroblast Growth Factor Receptor 1 Amplification in Non-Small Cell Lung Cancer by Quantitative Real-Time PCR , 2013, PloS one.

[2]  L. Bubendorf,et al.  Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer , 2014, British Journal of Cancer.

[3]  M. Ladanyi,et al.  Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib. , 2009, Archives of pathology & laboratory medicine.

[4]  S. Dacic,et al.  Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas , 2010, Modern Pathology.

[5]  S. J. Henley,et al.  Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004-2009. , 2014, Lung cancer.

[6]  G. Giaccone,et al.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, The Journal of molecular diagnostics : JMD.

[7]  S. O'toole,et al.  Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. , 2013, Lung cancer.

[8]  W. Sommergruber,et al.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.

[9]  M. Meyerson,et al.  Inhibitor-Sensitive FGFR 1 Amplification in Human Non-Small Cell Lung Cancer , 2011 .

[10]  Roy S Herbst,et al.  KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[11]  V. Seshan,et al.  Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  S. Ha,et al.  Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Beissner,et al.  Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas , 2013, Cancer cytopathology.

[14]  S. Monaco,et al.  A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. , 2010, Human pathology.

[15]  M. Meyerson,et al.  Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer , 2011, PloS one.

[16]  G. Scagliotti,et al.  Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  G. Dranitsaris,et al.  Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Mark Clemons,et al.  Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Elisabeth Brambilla,et al.  Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Hiromasa Yamamoto,et al.  Sequential Molecular Changes during Multistage Pathogenesis of Small Peripheral Adenocarcinomas of the Lung , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Lei-na Sun,et al.  Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice , 2011, Journal of experimental & clinical cancer research : CR.

[23]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[24]  A. McCullough.  Comprehensive genomic characterization of squamous cell lung cancers , 2013 .

[25]  J. Bergh,et al.  HER2 status in a population-derived breast cancer cohort: discordances during tumor progression , 2010, Breast Cancer Research and Treatment.

[26]  P. Jänne,et al.  Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  I. Petersen,et al.  Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer , 2010, Science Translational Medicine.

[28]  A. Rao,et al.  Reply to comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas , 2013, Cancer cytopathology.

[29]  R. Herbst,et al.  Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma , 2013, Cancer cytopathology.

[30]  I. Judson,et al.  A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors , 2008, Clinical Cancer Research.

[31]  K. Matsuo,et al.  Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  G. Giaccone,et al.  Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study , 2006, Clinical Cancer Research.

[33]  Y. Saga,et al.  Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU‐68) , 2005, International journal of cancer.

[34]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[35]  Mari Mino-Kenudson,et al.  FGFR1 Amplification in Squamous Cell Carcinoma of The Lung , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  A. Marchetti,et al.  Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. , 2009, Neoplasia.

[37]  F. Beca,et al.  Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites , 2014, Cancer cytopathology.